Pharmaceuticals

Avandia

After it was released in the U.S. in 1999, Avandia quickly became a popular drug to treat diabetes. In 2007, the FDA placed a black box warning on Avandia. Even though the FDA considered removing the drug from the market at that time, the drug’s manufacturer, GlaxoSmithKline, insisted that certain studies showed no increased health risk associated with Avandia use. In 2010, the FDA voted not to remove the drug from the market.

Baron & Budd stepped up to help protect people who have suffered from serious health problems due to Avandia use. In the litigation, plaintiffs alleged that Avandia caused an increased risk of heart attack and other physical harms, and that GlaxoSmithKline failed to provide adequate warnings about the risk.

Baron & Budd shareholder Steve Baron was a lead negotiator in a confidential settlement of approximately 17,000 Avandia cases.

Baron & Budd also obtained a $177 million settlement for seven states against manufacturer GlaxoSmithKline (GSK) regarding Avandia. The attorneys at Baron & Budd, along with co-counsel, represented the states of  New Mexico, South Carolina, Utah, Kentucky, Maryland, Mississippi and West Virginia. These seven states had opted-out of the multi-state litigation and decided to pursue independent litigation, which resulted in a much greater recovery than had they participated in the federal/ multi-state settlement.

GranuFlo

Baron & Budd represents approximately 1000 individuals who either suffered cardiac arrest or died during or after dialysis containing either GranuFlo or its sister product, NaturaLyte. In addition, Baron & Budd, along with co-counsel, represents the State of Mississippi against Fresenius Medical Care Holdings, Inc. and Fresenius, USA, Inc. regarding the fraudulent marketing of GranuFlo and NaturaLyte. Baron & Budd shareholder Burton LeBlanc serves on the Plaintiffs’ Steering Committee (PSC), a leadership committee that oversees all activity in the lawsuit, in the litigation surrounding dialysis product GranuFlo and its sister product, NaturaLyte. Read more.

Fen-Phen

Baron & Budd helped pursue compensation for those who, after taking the diet drug Fen-Phen, were left with serious health conditions, including heart disease and pulmonary hypertension. Baron & Budd attorneys helped oversee a global settlement.